Compare LMNR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMNR | TLSI |
|---|---|---|
| Founded | 1893 | 2010 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Farming/Seeds/Milling | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 270.2M |
| IPO Year | 2005 | N/A |
| Metric | LMNR | TLSI |
|---|---|---|
| Price | $12.68 | $4.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $20.00 | $7.00 |
| AVG Volume (30 Days) | 53.4K | ★ 126.5K |
| Earning Date | 06-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,723,000.00 | N/A |
| Revenue This Year | N/A | $35.45 |
| Revenue Next Year | $13.95 | $37.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.20 | $3.42 |
| 52 Week High | $17.11 | $7.95 |
| Indicator | LMNR | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 48.71 |
| Support Level | $12.54 | $4.28 |
| Resistance Level | $13.60 | $4.84 |
| Average True Range (ATR) | 0.39 | 0.22 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 38.05 | 38.61 |
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.